Breastfeeding by Women Living With Human Immunodeficiency Virus in a Resource-Rich Setting: A Case Series of Maternal and Infant Management and Outcomes.
暂无分享,去创建一个
M. Loutfy | A. Bitnun | S. Read | M. Yudin | D. Campbell | T. Barozzino | M. Baqi | J. MacGillivray | N. Nashid | S. Khan
[1] Ingrid A. Beck,et al. Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component , 2021, Journal of acquired immune deficiency syndromes.
[2] P. Vernazza,et al. Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting? , 2018, Swiss medical weekly.
[3] D. Moodley,et al. Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE) A Randomized, Open-Label, Clinical Trial , 2017, Journal of acquired immune deficiency syndromes.
[4] J. Brophy,et al. Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission , 2017, Journal of acquired immune deficiency syndromes.
[5] N. Rollins,et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis , 2017, Journal of the International AIDS Society.
[6] Janet Malek,et al. Should Providers Discuss Breastfeeding With Women Living With HIV in High-Income Countries? An Ethical Analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] T. F. Rinke de Wit,et al. Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk. , 2016, The Journal of antimicrobial chemotherapy.
[8] P. Musoke,et al. Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial , 2016, The Lancet.
[9] J. Brophy,et al. Safety of combination antiretroviral prophylaxis in high-risk HIV-exposed newborns: a retrospective review of the Canadian experience , 2016, Journal of the International AIDS Society.
[10] M. Hudgens,et al. Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis , 2015, AIDS.
[11] J. Overbaugh,et al. The role of cell-associated virus in mother-to-child HIV transmission. , 2014, The Journal of infectious diseases.
[12] D. Cohan,et al. Breastfeeding and HIV-infected women in the United States: harm reduction counseling strategies. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] J. Brophy,et al. Prevention of vertical HIV transmission and management of the HIV-exposed infant in Canada in 2014. , 2014, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[14] P. Van de Perre,et al. HIV-1 Reservoirs in Breast Milk and Challenges to Elimination of Breast-Feeding Transmission of HIV-1 , 2012, Science Translational Medicine.
[15] J. Overbaugh,et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission , 2008, AIDS.
[16] T. Ndung’u,et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. , 2005, The Journal of infectious diseases.
[17] C. Rousseau,et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. , 2004, The Journal of infectious diseases.